Investors Invited to Lead Class Action Against Capricor Therapeutics Over Securities Fraud Allegations

Opportunity for Investors in Capricor Therapeutics

Capricor Therapeutics, Inc. finds itself at the center of a class action lawsuit, as highlighted by the national shareholder rights litigation firm, Schall, Brown & Schwartz LLP (SBS). This lawsuit alleges violations of the Securities Exchange Act of 1934 and accompanies claims of securities fraud that have affected the company's shareholders significantly.

The class action pertains to shareholders of NASDAQ-listed Capricor who suffered financial losses between December 17, 2025, and July 26, 2026, a period that is crucial for understanding the unfolding events. The investors are urged to reach out to SBS to explore opportunities for lead plaintiff appointments, although it's important to note that participating as a lead plaintiff isn't a prerequisite for loss recovery.

Allegations Against Capricor

The complaint asserts that Capricor misled investors through false representations and omissions about its clinical product, Deramiocel. A primary concern is that the company altered its statistical analysis plan for clinical data without prior approval from the FDA. This change introduced significant risk regarding the FDA's approval of Capricor's Biologics License Application (BLA), which the company was likely to struggle to substantiate. Consequently, when these aspects came to light, investors bore the brunt of the revelation as it resulted in diminished stock value and associated losses.

SBS encourages affected shareholders to take action before the September 28, 2026 deadline, as this window offers a chance to hold Capricor accountable while potentially recovering losses incurred. Investors must understand that, until class certification occurs, they are not represented by legal counsel unless they explicitly join the action. However, opting out may leave them as absent class members without recourse.

The Role of SBS Law

Schall, Brown & Schwartz LLP is recognized for its dedication to protecting investors’ rights and specializing in securities class action lawsuits. With extensive expertise in litigation concerning shareholder rights, the firm aims to ensure that the affected investors receive thorough representation and advocacy in these challenging circumstances. Founding partners Brian Schall, Andrew Brown, and David Schwartz are committed to aggressively pursuing justice on behalf of investors, showcasing their reliability and commitment to the cause.

Investors interested in discussing their rights and options can consult with SBS without any charges. Contact information is readily available on their official website, which outlines the implications of participating in the class action and the broad benefits it can provide to those seeking justice in light of the alleged misconduct by Capricor.

In summary, the Capricor therapeutic case serves as a reminder of the importance of vigilance in the investment landscape. Investors are reassured that they are not alone in this battle for transparency and accountability—especially with firms like SBS at their side, ready to champion investor rights and navigate the complexities involved in class action lawsuits against major companies like Capricor Therapeutics.